Clinical Trial Update: 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating 506U78 for recurrent or refractory cutaneous T-cell lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sezary Syndrome

Drugs mentioned

• 506U78

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome | Phase 2 | Status: TERMINATED